Heart Disease Journals

Cardiology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Hamilton–Craig I et al. – There was no difference in the primary endpoint (a combination of AVR, CV death, non–fatal MI, congestive heart failure from AS progression, coronary revascularisation, hospitalised unstable angina and non–haemorrhagic stroke). Compared with placebo, CVD events were reduced by 4.4% from 20.1% to 15.7% in the simvastatin/ezetimibe group. Cancer incidence and cancer deaths were more frequent in the simvastatin/ezetimibe group. These differences were not related to any form of cancer and did not increase with increased duration of therapy.


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address